Related Experiment Videos
Severe thrombocytopenia associated with once-daily rifampin therapy
1School of Pharmacy, West Virginia University Medical Center, Morgantow 26506.
Abstract:
Rifampin-induced thrombocytopenia has been recognized as an immunological reaction associated with intermittent high-dose therapy, and rarely seen with daily low-dose regimens. Our patient was a 33-year-old male with Marfan's syndrome who was given rifampin 600 mg/d po along with intravenous vancomycin for the treatment of Staphylococcus epidermidis endocarditis. His platelet count dropped from a baseline of 519,000/mm3 to 4000/mm3 after four doses of rifampin. Petechiae were present on the lower extremities without the presence of other bleeding sites. Rifampin, low-dose aspirin, and dipyridamole were discontinued. His platelet count returned to normal nine days after discontinuation of therapy. With the increasing use of rifampin for the treatment of nontuberculosis infections, clinicians should recognize the possibility of this drug causing such serious immunological reactions as thrombocytopenia, hemolytic anemia, acute renal failure, and shock with daily or intermittent therapy.
Insights
Rifampin can cause serious immune reactions like thrombocytopenia (low platelet count), even with daily low doses. This case highlights the risk, emphasizing careful monitoring for adverse drug events.
Area of Science:
- Pharmacology
- Immunology
- Hematology
Background:
- Rifampin is an antibiotic commonly used for tuberculosis and other infections.
- Rifampin-induced thrombocytopenia is typically an immune-mediated reaction linked to high-dose, intermittent therapy.
- Rarely, this adverse effect has been observed with daily low-dose rifampin regimens.
Observation:
- A 33-year-old male with Marfan's syndrome developed severe thrombocytopenia after four doses of daily rifampin (600 mg/d).
- The patient's platelet count decreased from 519,000/mm3 to 4000/mm3, with petechiae on lower extremities.
- Rifampin, aspirin, and dipyridamole were discontinued, leading to platelet count normalization within nine days.
Findings:
- This case demonstrates that rifampin can induce severe thrombocytopenia even with standard daily low-dose therapy.
- The immunological reaction occurred rapidly, indicating a potential hypersensitivity response.
- Recovery of platelet count was observed after drug withdrawal, supporting a causal link.
Implications:
- Clinicians must be aware of the potential for serious immune-mediated adverse drug reactions to rifampin, including thrombocytopenia.
- Vigilance is crucial when prescribing rifampin for nontuberculosis infections, regardless of the dosing schedule.
- Monitoring platelet counts and other hematological parameters is recommended, especially during initial treatment phases.